Article
Designing new antitubercular isoniazid derivatives with improved reactivity and membrane trafficking abilities.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Dec 2021
de Faria Catarina Frazão, Moreira Tânia, Lopes Pedro, Costa Henrique, Krewall Jessica R, Barton Callie M, Santos Susana, Goodwin Douglas, Machado Diana, Viveiros Miguel, Machuqueiro Miguel, Martins Filomena
Abstract excerpt
Isoniazid (INH) is one of the two most effective first-line antitubercular drugs and is still used at the present time as a scaffold for developing new compounds to fight TB. In a previous study, we have observed that an INH derivative, an hydrazide N'-substituted with a C10acyl chain, was able to counterbalance its smaller reactivity with a higher membrane permeability. This resulted in an improved performance...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.